PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

– FREEDOM-DM1 15 mg/kg cohort demonstrated the highest mean splicing correction reported to date in DM1 patients – – FREEDOM2-DM1 5 mg/kg cohort on track to readout in Q1 2026, with all patients enrolled and having received at least one dose – – Recent $115 million financing extends cash runway